Alterity Therapeutics Limited PRNAF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -207.12% | -206.61% | -35.02% | -30.89% | 61.67% |
| Total Depreciation and Amortization | -4.65% | -5.21% | -19.83% | -22.22% | -11.52% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 479.93% | 479.04% | 203.48% | 194.23% | 34.10% |
| Change in Net Operating Assets | -129.57% | -129.51% | -66.67% | -61.57% | -67.13% |
| Cash from Operations | -326.69% | -325.98% | -27.97% | -24.06% | 62.95% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | 100.00% | -- | -- | -- |
| Cash from Investing | 100.00% | 100.00% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -19.73% | -19.73% | 2.93% | 2.93% | -232.43% |
| Issuance of Common Stock | -100.00% | -100.00% | 5,011.84% | 5,011.84% | 380.54% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 100.00% | -3,363.13% | -3,363.13% | -318.88% |
| Cash from Financing | -100.20% | -100.20% | 6,382.92% | 6,187.59% | 368.69% |
| Foreign Exchange rate Adjustments | 163.49% | 163.36% | 5.22% | 8.03% | -158.06% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -146.01% | -145.93% | 299.42% | 293.33% | 8,639.37% |